Press Releases

YOLKED® Sports Nutrition to Be Presenting Sponsor of Championship 7v7 Football Series in 2021
MYOS CORP Enters Exclusive Agreement with Science Biotech to Distribute Fortetropin® Products in Australia and New Zealand
MYOS CORP, Formerly Known as Myos Rens Technology, Inc., Issues Notice to its Shareholders
MYOS CORP Announces Positive Results from Mobility and Quality of Life Study in Geriatric and Arthritic Dogs at Kansas State University
MYOS CORP Enters into Agreement with a Leading Hong Kong Supplement Distributor, Smart Supplement Ltd., to Distribute YOLKED® Sports Nutrition Products in Hong Kong and Southeast Asian Countries
MYOS Corp Receives a New Patent from the United States Patent and Trademark Office Significantly Enhancing its Musculoskeletal Health Intellectual Property Portfolio
MYOS RENS TECHNOLOGY BOARD OF DIRECTORS approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding
MYOS RENS Technology Announces anticipated exchange ratio, immediately after the completion of the Merger
MYOS RENS Technology Announces Net Revenues Increase 39% for the Three Months Ended September 30, 2020
MYOS RENS Technology, Inc. Appoints The S3 Agency to Help Build Awareness of Muscle Health Importance
MYOS RENS Technology's Net Revenues Increase 114% and Operating Expenses Decrease 26% for the Three Months Ended June 30, 2020
MYOS RENS Technology Inc. Announces Settlement of Litigation with RENS Technology Inc.
University of California, Berkeley Researchers Publish Clinical Results Reporting that Fortetropin® Increased the Rate of Muscle Protein Synthesis in Older Adults
MYOS RENS Technology and MedAvail Inc. Announce Merger and Spin-Out of Muscle Health Business
MYOS RENS Launches RACE-Approved Continuing Education Course for Veterinarians on June 10, 2020
MYOS Announces Distribution Agreement with BodyLogicMD, a Leading Nationwide Network of Anti-Aging Medical Practices
MYOS RENS Partners with GetHealthy.store to Promote MYOS Longevity's Clinically-Backed Nutrition Products
MYOS RENS Enters into Agreement with Victor Medical to Distribute MYOS Canine Muscle Formula® Across Western United States
MYOS RENS Technology Reports First Quarter 2020 Financial Results Including a 95% Increase in Net Revenues
MYOS RENS Technology Announces the Date for First Quarter 2020 Conference Call and Webcast
MYOS RENS Announces that Multiple Top-Tier Pet Insurance Companies Now Cover its Canine Nutrition Products
MYOS RENS Announces Publication of Landmark Clinical Study on Recovery in Dogs Following TPLO Surgery
MYOS RENS Technology Reports a 187% Increase in Net Revenues for the Year Ended December 31, 2019
MYOS RENS Technology Announces Date of Fourth Quarter 2019 Financial Results, Conference Call and Webcast
MYOS RENS Partners with UNFI, a Nationwide Distributor of Natural, Organic and Specialty Food
MYOS RENS Announces Distribution and Co-Marketing Agreement with KVP International, a Leading Distributor of Veterinary Rehabilitation Products
MYOS RENS Hires College Football Icon and Inspirational Speaker Eric LeGrand as a Special Advisor for its YOLKED® Sports Nutrition Brand
MYOS Announces Distribution Partnership for Their Blockbuster Canine Muscle Formula with Chewy, a Leading Online Retailer of Pet Food and Pet-Related Products
MYOS RENS Technology to Provide Exciting Updates on New Product and Clinical Research at the Veterinary Meeting & Expo in Orlando, January 19-22, 2020
MYOS CEO Joseph Mannello Issues Letter to Shareholders
Albert Ahn, DVM, Expert in Animal Medicine, Joins MYOS as Strategic Adviser to Build Veterinary Business Focused on Muscle Health
MYOS to Introduce its Longevity Business with its Physician Muscle Health Formula at the World Congress on Anti-Aging Medicine in Las Vegas December 13-15, 2019
MYOS RENS' Fortetropin® Clinical Trial Results to be Presented by William J. Evans, Ph.D., at the International Conference on Frailty and Sarcopenia Research
MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders Summarizing Milestone Achievements and Ongoing Growth Strategy
MYOS RENS Technology Reports Third Quarter 2019 Financial Results Including Year-Over-Year Revenue Growth of 430%
MYOS RENS Technology Launches Exclusive 'Veterinarian Strength' Myos Canine Muscle Formula
MYOS RENS Technology Announces the Date for the Release of Third Quarter 2019 Financial Results, Conference Call and Webcast
MYOS RENS Technology Partners with the Texas Golf Association to Introduce Yolked® to Strategic Demographic
MYOS RENS Technology to Exhibit MYOS Canine Muscle Formula® at the New York Vet Show in New York City, November 7- 8, 2019
MYOS RENS Technology Enters into Research Agreement with McMaster University to Study Impact of Fortetropin® on Muscle Disuse Atrophy in Young Men
MYOS RENS Technology Kicks Off College Football Season with the Launch of the Yolked® Rose Bowl Stadium Sweepstakes
MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders Outlining First Half 2019 Accomplishments and Opportunities for Future Growth
MYOS RENS Technology Reports 75% Net Revenue Growth in Second Quarter, 109% Net Revenue Growth in First Half of 2019
MYOS RENS Technology Announces the Date for the Release of Second Quarter and First Half 2019 Results, Conference Call and Webcast
MYOS RENS Technology Congratulates the United States Women's National Soccer Team and Team Yolked® Member Carli Lloyd on Winning the 2019 FIFA Women's World Cup
MYOS RENS' Fortetropin® Shown to Increase the Rate of Muscle Protein Synthesis in Older Adults in Clinical Study Carried out at University of California, Berkeley
MYOS RENS Technology Announces Endorsement Partnership for Yolked® with Carli Lloyd, Two-Time Olympic Gold Medalist, FIFA Women's World Cup Champion, and Captain of the United States Women's National Soccer Team
MYOS RENS Technology to Present at the 9th Annual LD Micro Invitational in Los Angeles, CA
MYOS RENS Technology Reports 161% Increase in Revenues, 238% Increase in Gross Profit in First Quarter 2019
MYOS RENS Technology Announces the Date for the Release of First Quarter 2019 Results, Conference Call and Webcast
MYOS RENS Technology Signs Distribution Agreement with National Sales Associates, LLC
MYOS RENS Technology Reports Fourth Quarter and Fiscal 2018 Results
MYOS RENS Technology Announces the Date for the Release of Fourth Quarter and Fiscal Year 2018 Results, Conference Call and Webcast
MYOS RENS Technology Announces Initiation of a Study at Kansas State University to Evaluate the Impact of Fortetropin® on Quality of Life and Activity in Geriatric Dogs
MYOS RENS Technology Announces First Endorsement Deal for Yolked® with NBA Superstar Aaron Gordon
MYOS CEO Joseph Mannello Issues Letter to Shareholders Following Presentation at North American Veterinary Community (NAVC) Conference/VMX
MYOS RENS Technology Announces Study Results Demonstrating Fortetropin®, the Active Ingredient in Myos Canine Muscle Formula, Prevents Muscle Loss in Canines After Surgery and Enhances Recovery
MYOS RENS Technology Announces Upcoming Presentation of Results from a Kansas State University Study Evaluating the Impact of Fortetropin® on Canine Muscle Loss after Surgery, at a Major Veterinary Conference, January 20, 2019
MYOS RENS Technology Receives a New Patent from the United States Patent and Trademark Office
MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders
MYOS RENS Technology Announces Results of Its 2018 Annual Meeting of Stockholders
MYOS RENS Technology Launches 'Yolked®', Its Sports Nutrition Product, With The Vitamin Shoppe® Nationwide
MYOS RENS Technology Announces Approval of $1.2 Million in NJEDA NOL Program Tax Credits
MYOS RENS Technology Reports Financial Results for the Third Quarter of 2018 and Business Updates
MYOS RENS Technology Signs Distribution Agreement With Miller Veterinary Supply East To Bring Innovative MYOS Canine Muscle Formula™ To 6,000+ Veterinary Hospitals
MYOS RENS Technology Announces The Date For The Release Of Third Quarter 2018 Results, Conference Call And Webcast
Centers For Medicare and Medicaid Services Approves Reimbursement For Unique Fortetropin®-Based Enteral Nutrition Formula
MYOS RENS Technology To Exhibit MYOS Canine Muscle Formula™ At The Atlantic Coast Veterinary Conference, October 8-11, 2018
MYOS RENS Technology Reports 49% Increase In Net Revenues In Second Quarter Of 2018
MYOS RENS Technology Announces The Date For The Release Of Second Quarter And First Half 2018 Results, Conference Call And Webcast
MYOS RENS Technology Launches Advanced Veterinary Supplement Product For Dogs, Powered By Fortetropin®
MYOS RENS Technology Reports First Quarter Financial Results
MYOS RENS Technology Announces the Date for the Release of First Quarter 2018 Results, Conference Call and Webcast
MYOS RENS Technology Introduces New Sports Nutrition Product Line, Yolked™, and Earns Prestigious "Certified For Sport®" Certification From NSF International
MYOS RENS Technology to Present at the MicroCap Conference April 10 in New York City at the Essex House
MYOS RENS Technology CEO Joseph Mannello Provides Comments On Operational And Financial Results For Fiscal Year 2017
MYOS RENS Technology Reports Fourth Quarter And Fiscal 2017 Financial Results
MYOS RENS Technology, Inc. Announces Research Agreement with Rutgers University Focused on Discovery of Compounds and Products for Improving Muscle Health and Performance
MYOS RENS Technology Announces the Date for the Release of Fourth Quarter and Year Ended December 31, 2017 Results, Conference Call and Webcast
MYOS RENS Technology to Showcase Fortetropin® and the Qurr® Line of Muscle Health Products at the 2018 Arnold Sports Festival in Columbus, OH from March 2-4, 2018
MYOS RENS Technology Launches 30-Day Qurr® Fortetropin® Challenge
MYOS RENS Technology CEO Issues Shareholder Letter
MYOS RENS Technology Enters Into Research Agreement With University Of California, Berkeley To Study Effects Of Fortetropin® On Skeletal Muscle Protein Synthetic Rate In Older Men And Women
MYOS RENS Technology Reports Third Quarter 2017 Financial Results
MYOS RENS Technology Inc. Launches Collegiate Sports Marketing Platform
Pro Football Legends, the Commercial Marketing Arm of the NFL Alumni, Launches Partnership with MYOS RENS Technology Inc. in Optimal Bowl and Wellness Challenge
MYOS RENS Technology Inc. Appoints Joseph Mannello as Permanent Chief Executive Officer
MYOS RENS to Introduce the Qurr® Line of Muscle Health Products at 35th IDEA World Convention July 19-23, 2017 in Las Vegas
MYOS RENS Will Be Silver Sponsor at International Conference on Frailty and Sarcopenia Research (ICFSR)
MYOS RENS enters into agreement with Kansas State University to study impact of Fortetropin® on reducing muscle loss in dogs after joint surgery
MYOS RENS Technology to host April 4 interactive conference call on "Qurr" product launch
Are you Qurr-ious? MYOS Rens Technology Inc. Launches Qurr Product Line Powered by Fortetropin®, an All-Natural Ingredient Clinically Proven to Increase Muscle Size and Mass
'Qurr' line of revolutionary muscle-health and muscle-building products in newly-enhanced form set for March rollout
MYOS RENS Technology Inc. Adopts Shareholder Rights Plan
MYOS RENS Technology Inc. Announces $2,125,000 Registered Direct Offering
Dr. Robert Hariri, stem cell pioneer and chairman of MYOS RENS Technology, states that 'healthy muscle is key to overall health and wellness'
MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer
MYOS Reports Positive Results From Fortetropin(R) Clinical Study
MYOS Corporation Announces Corporate Name Change to MYOS RENS Technology Inc.
MYOS Corporation Announces Election of New Directors and Appointment of Ren Ren as Global Chairman
MYOS Corporation Announces the Initial Closing of a Strategic Investment by RENS Technology Inc.
MYOS Corporation Announces Strategic Investment by RENS Technology Inc.
Maintaining Muscle Linked to Preserving Healthy Brain Tissue
MYOS' Proprietary Muscle Building Technology Fortetropin: Foundation for New Dietary Recommendations
MYOS Corporation to Host Conference Call to Discuss Management Highlights
MYOS Corporation Launches Optimized Re Muscle Health(TM) Website and HealthTrac App
MYOS Corporation Issues Letter to Shareholders Highlighting Key Accomplishments
MYOS Corporation Publishes Research Article on the Impact of Fertility on the Chicken Egg Yolk Proteome in Peer-Reviewed Journal
MYOS Corporation Receives Health Canada Approval of Proprietary Ingredient Fortetropin(R)
MYOS Corporation Initiates Marketing Plan for Re Muscle Health(TM) Products
MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights
MYOS Corporation Initiates Clinical Study on Fortetropin(R) Dose Response
MYOS Corporation Announces the Re Muscle Health(TM) Series Powered by Fortetropin(R)
MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights
iHeart Radio's "HealthTech Talk" Show to Feature MYOS Corporation's Ingredient Fortetropin(TM) in Exclusive Interview With Company Chairman
MYOS Corporation to Present Mechanism of Action Data at the Experimental Biology Conference
Chairman Dr. Robert Hariri of MYOS Corporation to Be Interviewed Live on Clear Channel's "The Trader's Network Show"
MYOS Corporation Research Selected to Be Presented at International Conference on Molecular and Cellular Biology
MYOS Corporation's Preclinical Study of Fortetropin's(TM) Mechanism of Action Demonstrate Regulatory Effects on Three Key Muscle Health Pathways
MYOS Corporation to Present at the Eighth Annual OneMedForum Conference on January 13, 2015
MYOS Corporation Announces $1.81 Million Registered Direct Offering
MYOS Corporation Reports 2014 Third Quarter Results and Provides Business Update
MYOS Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on November 14, 2014
MYOS Corporation Announces Positive Safety Data Demonstrating Fortetropin's™ Lack of Adverse Effect on Serum Lipids and Cholesterol Levels
MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating Fortetropin's(TM) Anti-Inflammatory BioTherapeutic Properties
MYOS Corporation to Present Positive Clinical Data at 55th Annual Conference of the American College of Nutrition
MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct Clinical Metabolomic Studies in Subjects Using Fortetropin(TM)
MYOS Corporation to Present at the Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014
MYOS Corporation Reports 2014 Second Quarter Results
MYOS Corporation to Announce Second Quarter 2014 Financial Results on August 14, 2014
MYOS Corporation Reports Additional Clinical Data on the Impact of Fortetropin on Lean Body Mass, Fat Mass and Muscle Size in Male Subjects
MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer
MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin
MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin
MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules Targeting Sarcopenia and Cachexia
MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter, Ph.D., to Board of Directors
MYOS Corporation Announces Approval for Listing on the NASDAQ Capital Market
MYOS Corporation Sponsors Sixth Annual Edition of Scientific American Worldview
MYOS Corporation Establishes Research Relationship With Rutgers University in Muscle Science
MYOS Corporation Announces Appointment of Joseph C. DosSantos as Chief Financial Officer
MYOS Corporation Reports 2014 First Quarter Results
MYOS Corporation to Sponsor the 2014 Cancer Cachexia Conference
MYOS Corporation Teams Up With NFL Alumni in Optimal Bowl and Wellness Challenge
MYOS Corporation Studies Muscle and Strength Building Activity of Fortetropin in Resistance Trained Male Subjects
MYOS Corporation Reports 2013 Fourth Quarter and Full Year Results
MYOS Corporation Joins Scientific Working Group Aging in Motion to Develop Patient Centered Treatment Measures for Sarcopenia
MYOS Corporation Takes Steps to Make a Difference in the Fight Against Muscle Disease at the New Jersey MDA Muscle Walk
MYOS Corporation to Present Abstract on Lipidomic and Proteomic Studies of MYO-T12(R) at the International Conference on Frailty and Sarcopenia Research
MYOS Corporation Initiates Clinical Study of MYO-T12® in Adult Women
MYOS Corporation Appoints Christopher Pechock to Its Board of Directors
MYOS Corporation Announces Appointment of Robert C. Ashton, Jr., M.D., as Chief Medical Officer
MYOS Board of Directors Issues Letter to Shareholders
MYOS Corporation Announces 1-for-50 Reverse Stock Split Following Five Consecutive Quarters of Market Expansion and Revenue Growth
MYOS Corporation Closes $4.735 Million Private Placement
MYOS Corporation Announces Third Quarter Results;
MYOS Research to Be Presented at International Conference on Sarcopenia and Cachexia
MYOS to Study Synergistic Effects of Myostatin Inhibition on Testosterone-Mediated Muscle Growth; Brigham and Women's Hospital, a Teaching Affiliate of Harvard Medical School, to Conduct the Study
UPDATE: MYOS Reports Second Quarter 2013 Financial Results and Recent Key Operational Highlights
MYOS Reports Second Quarter 2013 Financial Results and Recent Key Operational Highlights
MYOS Signs Exclusive Supply Contract, Plans New Product R&D, With DIL
MYOS to Initiate a New Clinical Study on MYO-T12; Company Plans to Introduce Muscle Health Products for Women
MYOS Selected to Elite Global Food and Nutritional Technology Organization; Joins Heinz, Mars, Nestle, Pepsi as Members of German Institute for Food Technologies
MYOS Corporation Reports First Quarter 2013 Financial Results
MYOS Issues Shareholder Letter Highlighting Key Accomplishments
MYOS Corporation Reports Fourth Quarter and Year End Financial Results for 2012
MYOS Clinical Research Study Confirms "Beneficial Effect" of MYO-T12 in Suppressing Myostatin Levels
MYOS Corporation Appoints Glen R. Fleischer as Chief Executive Officer
MYOS Announces MYO-X Now Available in GNC; Vitamin Shoppe Soon to Follow
MYOS Appoints Sapna Srivastava as a Senior Advisor
MYOS Appoints Andrew J. Einhorn as Chief Financial Officer
MYOS Files Patent for MYO-T12 to Prevent Muscle Loss
MYOS Announces That MYO-X Is Now Available Online at GNC.com
MYOS Begins Groundbreaking Clinical Study on Muscle Health; Research Designed to Validate the Strengths of MYO-T12
MYOS Issues Special Letter to Shareholders: Company Committed to R&D, Developing Innovative Products and Formulations
MYOS Announces $5.6 Million Equity Private Placement
MYOS Names Veteran Biotechnology Executive Dr. Sol J. Barer to Chair Scientific Advisory Board
MYOS Appoints Astronaut Buzz Aldrin to Its Board of Directors
MYOS Signs Distribution Deal, Sees Year One Sales Exceeding $5 Million
Atlas Therapeutics Changes Its Name and Ticker Symbol to MYOS Corporation and "MYOS"; Launches New Corporate Website
MYO-T12(R) is Now Available on Bodybuilding.com
Atlas Therapeutics Releases Corporate Video and Provides Investor Updates
Atlas Therapeutics Corporation and MYO-T12 Sponsor World Renowned Jiu-Jitsu and MMA Champion Daniel Gracie
MYO-T12(R) is Now Available on Amazon.com
Photo Release -- Atlas Therapeutics Launches Online Media Blitz for MYO-T12(R)
Obesity Research and Treatment Expert, Dr. Louis Aronne, Joins Atlas Therapeutics' Board of Directors
Photo Release -- Atlas Therapeutics Corporation Signs Deal With Wayne Gretzky as National Spokesman for MYO-T12(R)... The World's First Clinically Validated Myostatin Inhibitor
RSS